Longeveron Inc

NASDAQ:LGVNUnited States

Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.

Contact Information

Headquarters

1951 NW 7th Ave, Ste 520MIAMI, FL, United States 33136

Phone

305-302-7158

Fax

302-674-5266

Executives

Chairman of the Board, Co-Founder, Chief Science Officer

Joshua Hare

Chief Executive Officer, Director

Wa'el Hashad

Co-Founder, Director

Donald Soffer

Chief Financial Officer, Executive Vice President

Lisa Locklear

General Counsel, Corporate Secretary, International Executive Director

Paul Lehr